Yoshiro Niitsu

Yoshiro Niitsu

Auto-generated profile, based on publicly available information

Yoshiro Niitsu

Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine, Sapporo, Japan

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2001 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JKJunji Kato
Junji Kato
KFKoshi Fujikawa
Koshi Fujikawa
MKMegumi Kanda
Megumi Kanda
NFNao Fukuda
Nao Fukuda
KSKatsunori Sasaki
Katsunori Sasaki
YNYoshiro Niitsu
Yoshiro Niitsu

1 December 2006 in Stem Cells
Verified
Journal Article
Open access
PDF file
TMTakuya Matsunaga
Takuya Matsunaga
ITIkuta Tanaka
Ikuta Tanaka
MKMasayoshi Kobune
Masayoshi Kobune
YKYutaka Kawano
Yutaka Kawano
MTMaki Tanaka
Maki Tanaka
YNYoshiro Niitsu
Yoshiro Niitsu
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology. STEM CELLS welcomes original articles and concise reviews describing basic laboratory investigations of stem cells and the translation of their clinical aspects of characterization and manipulation from the bench to patient care. The journal covers all aspects of stem cells embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; stem cell technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem cells; translational and clinical research; and regenerative medicine.

1 July 2004 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
TSTsutomu Sato
Tsutomu Sato
TMTakuro Machida
Takuro Machida
STSho Takahashi
Sho Takahashi
SISatoshi Iyama
Satoshi Iyama
YSYasushi Sato
Yasushi Sato
YNYoshiro Niitsu
Yoshiro Niitsu
Generation of reactive oxygen species (ROS) and activation of caspase cascade are both indispensable in Fas-mediated apoptotic signaling. Although ROS was presumed to affect the activity of the caspase cascade on the basis of findings that antioxidants inhibited the activation of caspases and that the stimulation of ROS by itself activated caspases, the mechanism by which these cellular events are integrated in Fas signaling is presently unclear. In this study, using human T cell leukemia Jurkat cells as well as an in vitro reconstitution system, we demonstrate that ROS are required for the formation of apoptosome. We first showed that ROS derived from mitochondrial permeability transition positively regulated the apoptotic events downstream of mitochondrial permeability transition. Then, we revealed that apoptosome formation in Fas-stimulated Jurkat cells was clearly inhibited by N-acetyl-l-cysteine and manganese superoxide dismutase by using both the immunoprecipitation and size-exclusion chromatography methods. To confirm these in vivo findings, we next used an in vitro reconstitution system in which in vitro-translated apoptotic protease-activating factor 1 (Apaf-1), procaspase-9, and cytochrome c purified from human placenta were activated by dATP to form apoptosome; the formation of apoptosome was markedly inhibited by reducing reagents such as DTT or reduced glutathione (GSH), whereas hydrogen peroxide prevented this inhibition. We also found that apoptosome formation was substantially impaired by GSH-pretreated Apaf-1, but not GSH-pretreated procaspase-9 or GSH-pretreated cytochrome c. Collectively, these results suggest that ROS plays an essential role in apoptosome formation by oxidizing Apaf-1 and the subsequent activation of caspase-9 and -3.

1 July 1998 in Blood
Verified
Journal Article
Open access
PDF file
YHYasuo Hirayama
Yasuo Hirayama
SSSumio Sakamaki
Sumio Sakamaki
TMTakuya Matsunaga
Takuya Matsunaga
TKTakashi Kuga
Takashi Kuga
HKHiroyuki Kuroda
Hiroyuki Kuroda
YNYoshiro Niitsu
Yoshiro Niitsu
The function of bone marrow (BM) stromal thrombopoietin (TPO) in megakaryopoiesis remains unknown. In the present study we attempted to clarify the pathophysiological implications of stromal TPO in normal subjects (NS) and in patients with idiopathic thrombocytopenic purpura (ITP), aplastic anemia (AA), and essential thrombocythemia (ET) by measuring TPO concentrations in BM and peripheral blood (PB) and by estimating the levels of stromal TPO mRNA with TaqMan fluorescence-based post–reverse transcription-polymerase chain reaction product detection system. The results showed that TPO concentrations in PB were significantly elevated in patients with ITP (34.9 ± 11.7 pg/mL) and AA (364.1 ± 153.5 pg/mL) but within normal range in patients with ET (each 20.0 and 22.1; NS, 22.1 ± 8.2 pg/mL). In all subjects, the TPO concentrations in BM correlated well with the PB levels, and the former were consistently higher than the latter. The concentrations of TPO in BM also correlated with the levels of TPO mRNA in stromal cells. Furthermore, expression levels of TPO mRNA clearly correlated with megakaryocyte counts in NS and patients with ITP, indicating that stromal TPO actually enhances megakaryopoiesis. Thus, our results in the present study indicate that TPO from BM stromal cells is considered to play an essential role for megakaryopoiesis under various patho-physiological conditions.

15 September 1999 in Blood
Verified
Journal Article
Open access
SSSumio Sakamaki
Sumio Sakamaki
YHYasuo Hirayama
Yasuo Hirayama
TMTakuya Matsunaga
Takuya Matsunaga
HKHiroyuki Kuroda
Hiroyuki Kuroda
TKToshiro Kusakabe
Toshiro Kusakabe
YNYoshiro Niitsu
Yoshiro Niitsu
The present study was designed to test the concept that platelets release a humoral factor that plays a regulatory role in megakaryopoiesis. The results showed that, among various hematoregulatory cytokines examined, transforming growth factor-β1 (TGF-β1) was by far the most potent enhancer of mRNA expression of bone marrow stromal thrombopoietin (TPO), a commitment of lineage specificity. The TPO, in turn, induced TGF-β receptors I and II on megakaryoblasts at the midmegakaryopoietic stage; at this stage, TGF-β1 was able to arrest the maturation of megakaryocyte colony-forming units (CFU-Meg). This effect was relatively specific when compared with its effect on burst-forming unit-erythroid (BFU-E) or colony-forming unit–granulocyte-macrophage (CFU-GM). In patients with idiopathic thrombocytopenic purpura (ITP), the levels of both TGF-β1 and stromal TPO mRNA were correlatively increased and an arrest of megakaryocyte maturation was observed. These in vivo findings are in accord with the aforementioned in vitro results. Thus, the results of the present investigation suggest that TGF-β1 is one of the pathophysiological feedback regulators of megakaryopoiesis.

20 November 2012 in Gut
Verified
Journal Article
Open access
PDF file
HIHirotoshi Ishiwatari
Hirotoshi Ishiwatari
YSYasushi Sato
Yasushi Sato
KMKazuyuki Murase
Kazuyuki Murase
AYAkihiro Yoneda
Akihiro Yoneda
RFRyosuke Fujita
Ryosuke Fujita
YNYoshiro Niitsu
Yoshiro Niitsu
Background and objective: Fibrosis associated with chronic pancreatitis is an irreversible lesion that can disrupt pancreatic exocrine and endocrine function. Currently, there are no approved treatments for this disease. We previously showed that siRNA against collagen-specific chaperone protein gp46, encapsulated in vitamin A-coupled liposomes (VA-lip-siRNAgp46), resolved fibrosis in a model of liver cirrhosis. This treatment was investigated for pancreatic fibrosis induced by dibutyltin dichloride (DBTC) and cerulein in rats. Methods: Specific uptake of VA-lip-siRNAgp46, conjugated with 6′-carboxyfluorescein (FAM) by activated pancreatic stellate cells (aPSCs), was analysed by fluorescence activated cell sorting (FACS). Intracellular distribution of VA-lip-siRNAgp46-FAM was examined by fluorescent microscopy. Suppression of gp46 expression by VA-lip-siRNAgp46 was assessed by immunoblotting. Collagen synthesis in aPSCs was assayed by dye-binding. Specific delivery of VA-lip-siRNAgp46 to aPSCs in DBTC rats was verified following intravenous VA-lip-siRNA-FAM and 3 H-VA-lip-siRNAgp46. The effect of VA-lip-siRNA on pancreatic histology in DBTC- and cerulein-treated rats was determined by Azan-Mallory staining and hydroxyproline content. Results: FACS analysis revealed specific uptake of VA-lip-siRNAgp46-FAM through the retinol binding protein receptor by aPSCs in vitro. Immunoblotting and collagen assay verified knockdown of gp46 and suppression of collagen secretion, respectively, by aPSCs after transduction of VA-lip-siRNAgp46. Specific delivery of VA-lip-siRNAgp46 to aPSCs in fibrotic areas in DBTC rats was confirmed by fluorescence and radioactivity 24 h after the final injection. 10 systemic VA-lip-siRNAgp46 treatments resolved pancreatic fibrosis, and suppressed tissue hydroxyproline levels in DBTC- and cerulein-treated rats. Conclusion: These data suggest the therapeutic potential of the present approach for reversing pancreatic fibrosis.